Hikal has appointed Sameer Hiremath as its Chairman and Managing Director. The Board of Directors approved the five-year term on August 26, 2026.

The appointment is subject to shareholder approval at the ensuing Annual General Meeting. Hiremath will assume office on October 1, 2026, serving until September 30, 2031.

Leadership Transition

Hiremath currently serves as Vice Chairman and Managing Director. He brings nearly three decades of experience with the company. His background includes leadership in strategy, business development, research, technology, manufacturing, and operations.

He holds a degree in Petrochemical Engineering. He also possesses an MBA and an MS in Information Technology from Boston University, USA.

Regulatory Compliance

The Nomination and Remuneration Committee and Audit Committee recommended the appointment. The board unanimously approved it during a meeting that commenced at 11:30 am and concluded at 1:12 pm.

The company confirmed that Hiremath is not debarred from holding office by any SEBI order or other authority. He is the son of Jai Hiremath and Sugandha Hiremath.

This disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Hikal Limited reported a consolidated net loss of ₹74 million for the quarter ended June 30, 2026 (Q1FY27), a significant improvement from the ₹224 million loss recorded in the corresponding period of FY25. The company’s total revenue from operations rose 6% year-on-year to ₹4,046 million, driven primarily by growth in its Pharmaceuticals segment. Standalone results mirrored this trend, with a net loss of ₹75 million compared to ₹227 million in Q1FY25. The narrowing loss reflects better operational performance in key segments and favorable exceptional items, including a ₹89 million reduction in employee benefit liabilities due to salary restructuring.

The Board of Directors approved the unaudited financial results at a meeting held on August 06, 2026. The results were reviewed by the Audit Committee on August 05, 2026. S R B C & Co LLP, the statutory auditor, issued an unmodified limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Hikal Limited published its financial results in Business Standard (English) and Mumbai Lakshadeep (Marathi) on August 07, 2026, pursuant to Regulation 30 read with Schedule III and Regulation 47 of the SEBI LODR Regulations, 2015. The trading window for designated persons will re-open on August 09, 2026, following its closure since July 01, 2026.

Segment Performance

The Pharmaceuticals segment contributed ₹2,333 million to revenue, up from ₹2,026 million in Q1FY25. It returned to profitability with a segment result of ₹75 million, reversing a loss of ₹261 million in the prior year. In contrast, the Crop Protection segment saw revenue decline to ₹1,695 million from ₹1,778 million, reporting a segment loss of ₹60 million compared to a profit of ₹173 million previously. This divergence highlights shifting demand dynamics and potential regulatory headwinds in the agrochemical space.

Key Financial Metrics

Hikal's operational efficiency showed marked improvement, with EBITDA rising to ₹370 million from ₹251 million in Q1FY25, while EBITDA margin expanded to 9.20% from 6.60% over the same period. Total expenses stood at ₹4,234 million, slightly lower than the ₹4,235 million incurred in the standalone books. Finance costs remained stable at ₹149 million. Depreciation and amortization expenses increased to ₹427 million from ₹394 million in Q1FY25. Other income was ₹18 million, down from ₹66 million in the previous quarter but up from ₹10 million in Q1FY25. Tax expense was ₹25 million, comprising deferred tax only, as current tax was nil following a reversal of provisions.

Strategic Updates and Outlook

Management highlighted that the US FDA remediation program is on track, with a re-inspection expected towards the end of FY27. Since receiving the warning letter in August 2025, Hikal has maintained continuous dialogue with the regulator and has not lost any customer contracts in the last 12 months. The newly commissioned cGMP pilot plant in Panoli is operational, increasing DMF filing capability from 2-3 to 6-7 filings per year.

The Animal Health business, which scaled over ₹100 crore in annual turnover last year, continues to grow with long-term CDMO contracts. Management guided for this segment to reach ₹400 crore+ in revenue by FY30, with expected EBITDA margins of 20%+. Additionally, the Personal Care division has commenced commercial production at Panoli, with revenue expected by end-FY27. Management projects Personal Care could cross ₹200 crore in revenue within three years, with EBITDA margins exceeding 20%.

For FY27, Hikal expects full-year revenue growth in the range of 14%-16% and EBITDA growth of 25%-30%. Crop Protection is expected to see marginal growth, while Pharma and Animal Health drive the expansion. Net debt reduced from approximately ₹815 crore in FY24 to ₹685 crore by end-FY26, with a debt-to-equity ratio of 0.53.

What the Numbers Show

The improvement in net loss is largely attributable to the Pharmaceuticals segment's return to profitability, a ₹89 million exceptional gain from salary restructuring, and a meaningful expansion in EBITDA margins. However, the Crop Protection segment's decline signals ongoing challenges, potentially exacerbated by the USFDA warning letter issued in August 2025 regarding the Jigani facility, which continues to impact Pharma sales. Additionally, the company faces legal uncertainty over alleged environmental non-compliance, with a matter pending before the Supreme Court of India involving a potential compensation of ₹174.5 million, though no further provision has been made as of this quarter.

The shift in strategic focus is evident in capital allocation: while Crop Protection sees only marginal growth expectations, significant investments are being directed toward high-margin Allied Pharma (Animal Health) and Personal Care. With these two emerging segments projected to contribute significantly to future top-line and boasting margin profiles superior to legacy Crop Protection, Hikal’s long-term earnings power hinges on the successful execution of its FDA remediation and the ramp-up of these new platforms.